This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Astex President Awarded Prous Institute-Overton And Meyer Award For New Technologies In Drug Discovery

DUBLIN, Calif., Aug. 20, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that its president and director, Harren Jhoti, PhD, will be presented with the 2012 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry. The biennial award recognizes research and innovation with respect to technology in drug discovery.

"I am honored to be bestowed this award by the Executive Committee of the European Federation for Medicinal Chemistry," said Dr. Jhoti. "This award recognizes the leading position that the Astex team has established in fragment-based drug discovery, a technique now widely used by the pharmaceutical sector to discover high quality drug candidates.  It is my hope that our contributions to fragment-based drug discovery will help to produce effective medicines."

Dr. Jhoti will be presented with the award at the 2012 meeting of the European Federation for Medicinal Chemistry - International Symposium on Medicinal Chemistry (EFMC-ISMC) in Berlin, Germany September 2 - 6, 2012, and will give a keynote lecture.

About Harren Jhoti, PhD

Dr. Harren Jhoti has served as Astex Pharmaceuticals president and member of the Board of Directors since the company's formation in July 2011.  He co-founded Astex Therapeutics in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive.  Dr. Jhoti was named by the Royal Society of Chemistry as "Chemistry World Entrepreneur of the Year" for 2007.  He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005.  Dr. Jhoti served as a non-executive director of Iconix Inc.  Before starting up Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999).  Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University.  He received a BSc (Hons) in Biochemistry in 1985 and a PhD in Protein Crystallography from the University of London in 1989.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs